- Home
- IMCR vs RNW Comparison
IMCR vs RNW Comparison
Compare IMCR & RNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMCR | RNW |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMCR | RNW |
|---|---|---|
| Price | $33.73 | $5.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $67.00 | $7.25 |
| AVG Volume (30 Days) | 280.5K | ★ 2.0M |
| Earning Date | 11-06-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 413.66 |
| EPS | N/A | ★ 0.26 |
| Revenue | $379,590,000.00 | ★ $1,382,164,625.00 |
| Revenue This Year | $32.28 | N/A |
| Revenue Next Year | $10.66 | $17.07 |
| P/E Ratio | ★ N/A | $21.60 |
| Revenue Growth | 28.11 | ★ 46.76 |
| 52 Week Low | $23.15 | $5.05 |
| 52 Week High | $40.72 | $8.24 |
Technical Indicators
Market Signals| Indicator | IMCR | RNW |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 37.43 |
| Support Level | $34.00 | $5.05 |
| Resistance Level | $36.64 | $5.69 |
| Average True Range (ATR) | 1.50 | 0.23 |
| MACD | -0.33 | 0.02 |
| Stochastic Oscillator | 10.33 | 31.96 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About RNW ReNew Energy Global plc
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.